Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2002

View Archived Issues

New antibacterial compounds prepared at Biochemie

Novel gpIbIX antagonists in the Merck pipeline

CDK inhibitors useful for cancer, autoimmune disorders and other conditions

Antitumor tyrosine kinase inhibitors prepared at AstraZeneca

PDE4 inhibitors and their use described by German researchers

New antifungal benzodiazepines reported by Janssen

Gedeon Richter patents NR2B-selective NMDA antagonists

Korean researchers identify antitumor quinolinediones

First trial of FGF-1 gene therapy in critical limb ischemia yields positive results

Trialkylglycine neuroprotectants with novel mechanism of action

Chinese patients respond well to VEGF-based gene therapy for critical limb ischemia

p38 MAPK inhibitor exerts beneficial effects following myocardial infarction in rats

Selective inhibition of PDGF-B prevents vascular remodeling in perinatal pulmonary hypertension

CCR3 receptor antagonists associated with partial inhibition of lung eosinophilia in asthma

Bio-Vant TB vaccine induces antibody responses in mouse model

Crucell and NIAID to develop Ebola vaccine

Immunex shareholders approve Amgen merger

Incara to develop catalytic antioxidants as adjunctive agents in cancer treatment

Actonel 35 mg approved for once-weekly dosing in postmenopausal osteoporosis

E.U. approval for Avonex for early use in high-risk MS patients

Cardiome acquires Oxyprim data

Vitamin D3 analogue arrests development of autoimmune diabetes

MorphoSys and ProChon expand anticancer antibodies collaboration

BHT-920 exhibits decongestant activity with an improved cardiovascular profile in the cat

Pharmacological characterization of the alpha-adrenoceptor agonists oxymetazoline and PGE-6201204

Adenosine A2A agonist CGS-21680 inhibits pulmonary inflammation induced by cigarette smoke in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...